These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
632 related articles for article (PubMed ID: 31412228)
21. Impact factors for the outcome of the first Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649 [TBL] [Abstract][Full Text] [Related]
22. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment. Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436 [TBL] [Abstract][Full Text] [Related]
23. Selective Use of Radioactive Iodine Therapy for Papillary Thyroid Cancers With Low or Lower-Intermediate Recurrence Risk. Grani G; Lamartina L; Alfò M; Ramundo V; Falcone R; Giacomelli L; Biffoni M; Filetti S; Durante C J Clin Endocrinol Metab; 2021 Mar; 106(4):e1717-e1727. PubMed ID: 33377969 [TBL] [Abstract][Full Text] [Related]
24. Clinicopathological features affecting the efficacy in Xu X; Li C; Yu X; Wang G; Guo Y; Ni H; Zhao W; Wang Y; Dong B Front Endocrinol (Lausanne); 2024; 15():1382009. PubMed ID: 39086895 [TBL] [Abstract][Full Text] [Related]
25. Five-Year Oncologic Outcome and Surgical Completeness of Transoral Robotic Thyroidectomy for Papillary Thyroid Carcinoma: Comparison with Conventional Transcervical Thyroidectomy Using Propensity Score Matching. Lee SJ; Ryu SR; Ji YB; Song CM; Park JH; Kim DS; Tae K Ann Surg Oncol; 2023 Apr; 30(4):2256-2264. PubMed ID: 36602660 [TBL] [Abstract][Full Text] [Related]
26. Predicting factors and clinical outcome of biochemical incomplete response in middle eastern differentiated thyroid carcinoma. Parvathareddy SK; Siraj AK; Ahmed SO; Annaiyappanaidu P; Al-Rasheed M; Al-Haqawi W; Qadri Z; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS Endocrine; 2024 Oct; 86(1):268-275. PubMed ID: 38696058 [TBL] [Abstract][Full Text] [Related]
27. Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer. Iwano S; Ito S; Kamiya S; Ito R; Kato K; Naganawa S Nagoya J Med Sci; 2020 May; 82(2):205-215. PubMed ID: 32581401 [TBL] [Abstract][Full Text] [Related]
28. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression. Lango M; Flieder D; Arrangoiz R; Veloski C; Yu JQ; Li T; Burtness B; Mehra R; Galloway T; Ridge JA Thyroid; 2013 Sep; 23(9):1099-105. PubMed ID: 23421588 [TBL] [Abstract][Full Text] [Related]
29. Response to Surgery Assessments for Sparing Radioiodine Remnant Ablation in Intermediate-Risk Papillary Thyroid Cancer. Zhang X; Liu JR; Mu ZZ; Cheng XQ; Lin YS J Clin Endocrinol Metab; 2023 May; 108(6):1330-1337. PubMed ID: 36567646 [TBL] [Abstract][Full Text] [Related]
30. PROGNOSIS OF HIGH-RISK PAPILLARY THYROID CANCER PATIENTS WITH PRE-ABLATION STIMULATED TG <1 NG/ML. Tian T; Kou Y; Huang R; Liu B Endocr Pract; 2019 Mar; 25(3):220-225. PubMed ID: 30913010 [TBL] [Abstract][Full Text] [Related]
31. Prognostic value of post-ablation stimulated thyroglobulin in differentiated thyroid cancer patients with biochemical incomplete response: a bi-center observational study. Wang Y; Wu J; Jiang L; Zhang X; Liu B Endocrine; 2022 Apr; 76(1):109-115. PubMed ID: 35094313 [TBL] [Abstract][Full Text] [Related]
32. Analysis of delayed initial radioactive iodine therapy and clinical outcomes in papillary thyroid cancer: a two-center retrospective study. He T; Li M; Gao ZL; Li XY; Zhong HR; Ding CS; Cai HW Nucl Med Commun; 2024 Sep; 45(9):779-787. PubMed ID: 38832411 [TBL] [Abstract][Full Text] [Related]
33. Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial. Dong P; Qu Y; Yang L; Xiao L; Huang R; Li L Clin Endocrinol (Oxf); 2021 Nov; 95(5):782-789. PubMed ID: 34368999 [TBL] [Abstract][Full Text] [Related]
34. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA. Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694 [TBL] [Abstract][Full Text] [Related]
35. Long-term clinical outcomes and prognostic factors for patients with papillary thyroid carcinoma with other organ invasions after adjuvant radioactive iodine. Kawamoto T; Shikama N; Fukumori T; Hoshi M; Yamada T Endocrine; 2023 Apr; 80(1):79-85. PubMed ID: 36367673 [TBL] [Abstract][Full Text] [Related]
36. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer. Cao J; Zhu X; Sun Y; Li X; Yun C; Zhang W Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3470-3481. PubMed ID: 35501518 [TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer. Sabet A; Binse I; Grafe H; Ezziddin S; Görges R; Poeppel TD; Bockisch A; Rosenbaum-Krumme SJ Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1988-94. PubMed ID: 27118127 [TBL] [Abstract][Full Text] [Related]
38. Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma. Kim Y; Roh JL; Song D; Cho KJ; Choi SH; Nam SY; Kim SY J Surg Oncol; 2020 Oct; 122(5):906-913. PubMed ID: 32588461 [TBL] [Abstract][Full Text] [Related]
39. Predictive Role of Serum Thyroglobulin after Surgery and before Radioactive Iodine Therapy in Patients with Thyroid Carcinoma. Signore A; Lauri C; Di Paolo A; Stati V; Santolamazza G; Capriotti G; Prosperi D; Tofani A; Valabrega S; Campagna G Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296937 [TBL] [Abstract][Full Text] [Related]
40. Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer. Li H; Zhang YQ; Wang C; Zhang X; Li X; Lin YS Clin Endocrinol (Oxf); 2018 Apr; 88(4):601-606. PubMed ID: 29338092 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]